Comparison of the Adverse Event Profile of TheraSphere® with SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review

Joseph Ralph Kallini, Ahmed Gabr, Kristian Thorlund, Chakrapani Balijepalli, Dieter Ayres, Steve Kanters, Shanil Ebrahim, Edward Mills, Robert J Lewandowski, Riad Salem*

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

To compare the safety profiles of TheraSphere® (glass) and SIR-Spheres® (resin) Y90 microspheres for the treatment of hepatocellular carcinoma. A systematic review was conducted using the databases MEDLINE, Embase, and Cochrane Trials Register to identify all relevant studies. Baseline characteristics and adverse events of all grades related to gastrointestinal, hepatobiliary, and respiratory systems were collected along with commonly reported outcomes related to post-embolization syndrome. For all outcomes, data from each study were tabulated for each intervention. Adverse events and patients were summed across studies on TheraSphere® and SIR-Spheres®, respectively, and the resulting proportion of patients experiencing an outcome for both interventions was calculated. Thirty-one observational studies were included in the review. In the adverse events of all grades, more patients treated with resin microspheres reported gastric ulcers, hepatic encephalopathy, cholecystitis, hepatic failure, and pleural effusion. Patients treated with resin microspheres also had more hepatobiliary adverse events of grade 3 or higher. In the events related to post-embolization syndrome, glass microspheres exhibited a similar safety profile compared to resin microspheres. Ascites and nausea grade 3 or higher were recorded more frequently with glass microsphere treatment. Based on this review of the published literature, glass microspheres exhibit a safety profile with fewer gastrointestinal and pulmonary adverse events compared to resin microspheres in the treatment of hepatocellular carcinoma.

Original languageEnglish (US)
Pages (from-to)1033-1043
Number of pages11
JournalCardiovascular and Interventional Radiology
Volume40
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Microspheres
Hepatocellular Carcinoma
Glass
Therapeutics
Safety
Cholecystitis
Hepatic Encephalopathy
Liver Failure
Pleural Effusion
Stomach Ulcer
Ascites
MEDLINE
Respiratory System
Nausea
Observational Studies
Databases
Lung

Keywords

  • Adverse event
  • HCC
  • Hepatocellular carcinoma
  • SIR-Spheres
  • Safety
  • TheraSphere
  • Y90
  • Yttrium-90

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Kallini, Joseph Ralph ; Gabr, Ahmed ; Thorlund, Kristian ; Balijepalli, Chakrapani ; Ayres, Dieter ; Kanters, Steve ; Ebrahim, Shanil ; Mills, Edward ; Lewandowski, Robert J ; Salem, Riad. / Comparison of the Adverse Event Profile of TheraSphere® with SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma : A Systematic Review. In: Cardiovascular and Interventional Radiology. 2017 ; Vol. 40, No. 7. pp. 1033-1043.
@article{cafd51c6586e487eb49e40dc9ec824bc,
title = "Comparison of the Adverse Event Profile of TheraSphere{\circledR} with SIR-Spheres{\circledR} for the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review",
abstract = "To compare the safety profiles of TheraSphere{\circledR} (glass) and SIR-Spheres{\circledR} (resin) Y90 microspheres for the treatment of hepatocellular carcinoma. A systematic review was conducted using the databases MEDLINE, Embase, and Cochrane Trials Register to identify all relevant studies. Baseline characteristics and adverse events of all grades related to gastrointestinal, hepatobiliary, and respiratory systems were collected along with commonly reported outcomes related to post-embolization syndrome. For all outcomes, data from each study were tabulated for each intervention. Adverse events and patients were summed across studies on TheraSphere{\circledR} and SIR-Spheres{\circledR}, respectively, and the resulting proportion of patients experiencing an outcome for both interventions was calculated. Thirty-one observational studies were included in the review. In the adverse events of all grades, more patients treated with resin microspheres reported gastric ulcers, hepatic encephalopathy, cholecystitis, hepatic failure, and pleural effusion. Patients treated with resin microspheres also had more hepatobiliary adverse events of grade 3 or higher. In the events related to post-embolization syndrome, glass microspheres exhibited a similar safety profile compared to resin microspheres. Ascites and nausea grade 3 or higher were recorded more frequently with glass microsphere treatment. Based on this review of the published literature, glass microspheres exhibit a safety profile with fewer gastrointestinal and pulmonary adverse events compared to resin microspheres in the treatment of hepatocellular carcinoma.",
keywords = "Adverse event, HCC, Hepatocellular carcinoma, SIR-Spheres, Safety, TheraSphere, Y90, Yttrium-90",
author = "Kallini, {Joseph Ralph} and Ahmed Gabr and Kristian Thorlund and Chakrapani Balijepalli and Dieter Ayres and Steve Kanters and Shanil Ebrahim and Edward Mills and Lewandowski, {Robert J} and Riad Salem",
year = "2017",
month = "7",
day = "1",
doi = "10.1007/s00270-017-1594-4",
language = "English (US)",
volume = "40",
pages = "1033--1043",
journal = "CardioVascular and Interventional Radiology",
issn = "7415-5101",
publisher = "Springer Verlag",
number = "7",

}

Comparison of the Adverse Event Profile of TheraSphere® with SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma : A Systematic Review. / Kallini, Joseph Ralph; Gabr, Ahmed; Thorlund, Kristian; Balijepalli, Chakrapani; Ayres, Dieter; Kanters, Steve; Ebrahim, Shanil; Mills, Edward; Lewandowski, Robert J; Salem, Riad.

In: Cardiovascular and Interventional Radiology, Vol. 40, No. 7, 01.07.2017, p. 1033-1043.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of the Adverse Event Profile of TheraSphere® with SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma

T2 - A Systematic Review

AU - Kallini, Joseph Ralph

AU - Gabr, Ahmed

AU - Thorlund, Kristian

AU - Balijepalli, Chakrapani

AU - Ayres, Dieter

AU - Kanters, Steve

AU - Ebrahim, Shanil

AU - Mills, Edward

AU - Lewandowski, Robert J

AU - Salem, Riad

PY - 2017/7/1

Y1 - 2017/7/1

N2 - To compare the safety profiles of TheraSphere® (glass) and SIR-Spheres® (resin) Y90 microspheres for the treatment of hepatocellular carcinoma. A systematic review was conducted using the databases MEDLINE, Embase, and Cochrane Trials Register to identify all relevant studies. Baseline characteristics and adverse events of all grades related to gastrointestinal, hepatobiliary, and respiratory systems were collected along with commonly reported outcomes related to post-embolization syndrome. For all outcomes, data from each study were tabulated for each intervention. Adverse events and patients were summed across studies on TheraSphere® and SIR-Spheres®, respectively, and the resulting proportion of patients experiencing an outcome for both interventions was calculated. Thirty-one observational studies were included in the review. In the adverse events of all grades, more patients treated with resin microspheres reported gastric ulcers, hepatic encephalopathy, cholecystitis, hepatic failure, and pleural effusion. Patients treated with resin microspheres also had more hepatobiliary adverse events of grade 3 or higher. In the events related to post-embolization syndrome, glass microspheres exhibited a similar safety profile compared to resin microspheres. Ascites and nausea grade 3 or higher were recorded more frequently with glass microsphere treatment. Based on this review of the published literature, glass microspheres exhibit a safety profile with fewer gastrointestinal and pulmonary adverse events compared to resin microspheres in the treatment of hepatocellular carcinoma.

AB - To compare the safety profiles of TheraSphere® (glass) and SIR-Spheres® (resin) Y90 microspheres for the treatment of hepatocellular carcinoma. A systematic review was conducted using the databases MEDLINE, Embase, and Cochrane Trials Register to identify all relevant studies. Baseline characteristics and adverse events of all grades related to gastrointestinal, hepatobiliary, and respiratory systems were collected along with commonly reported outcomes related to post-embolization syndrome. For all outcomes, data from each study were tabulated for each intervention. Adverse events and patients were summed across studies on TheraSphere® and SIR-Spheres®, respectively, and the resulting proportion of patients experiencing an outcome for both interventions was calculated. Thirty-one observational studies were included in the review. In the adverse events of all grades, more patients treated with resin microspheres reported gastric ulcers, hepatic encephalopathy, cholecystitis, hepatic failure, and pleural effusion. Patients treated with resin microspheres also had more hepatobiliary adverse events of grade 3 or higher. In the events related to post-embolization syndrome, glass microspheres exhibited a similar safety profile compared to resin microspheres. Ascites and nausea grade 3 or higher were recorded more frequently with glass microsphere treatment. Based on this review of the published literature, glass microspheres exhibit a safety profile with fewer gastrointestinal and pulmonary adverse events compared to resin microspheres in the treatment of hepatocellular carcinoma.

KW - Adverse event

KW - HCC

KW - Hepatocellular carcinoma

KW - SIR-Spheres

KW - Safety

KW - TheraSphere

KW - Y90

KW - Yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=85014015731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014015731&partnerID=8YFLogxK

U2 - 10.1007/s00270-017-1594-4

DO - 10.1007/s00270-017-1594-4

M3 - Article

C2 - 28246879

AN - SCOPUS:85014015731

VL - 40

SP - 1033

EP - 1043

JO - CardioVascular and Interventional Radiology

JF - CardioVascular and Interventional Radiology

SN - 7415-5101

IS - 7

ER -